I was told last week about the mother of an acquaintance in Chicago. His mother has had Vertebral Fractures again and again and again. After each fracture she has been...
If you fracture, your risk of a second fracture within a year is 3 to 5 times as great! If that first or second fracture is a hip, you have...
National Bone Health treatment goals are changing for those patients with high fracture risk. Simply preserving bones already at a too high fracture risk never made much sense to this...
Recently I wrote about our participation in a clinical trial offering the anabolic Tymlos (Abaloparatide) to men. Now we have been approved for participation in another Tymlos (Abaloparatide) trial –...
American Society for Bone & Mineral Research Annual Meeting 2019 starts tomorrow. Jon Hennings, ARNP and I will be there hoping to see and hear the latest studies about the...
FDA approved clinical trials are a well established way to gain access to medications not yet available to the general public. Most people have heard of individuals taking experimental treatments...
We now have a third anabolic medication to build new bone. Evenity is really different from the other anabolics, Forteo (teriparatide) and Tymlos (abaloparatide). Forteo and Tymlos are daily shots based...
Our goal is NO NEW FRACTURES. Therefore, Treat to Target means a FRAX score of <20% for “major osteoporotic” and <3% for hip fracture. Alternately, T-score of better than -1.5 if...
The FDA approved Tymlos (Abaloparatide) in June for use in women diagnosed with osteoporosis. Unfortunately most patients are unlikely to obtain insurance coverage for Tymlos until January or February 2018. Tymlos...